IP Library Granted Patent US 11,371,028
Granted Patent B2
US 11,371,028 · App. 17/156,704 · Granted Jun 28, 2022

Variant DNA polymerases having improved properties and method for improved isothermal amplification of a target DNA

Inventors: Jennifer Ong (Salem, MA); Nathan Tanner (West Newbury, MA); Yinhua Zhang (North Reading, MA); Yanxia Bei (Ipswich, MA); Vladimir Potapov (Auburndale, MA)
Assignee: New England Biolabs, Inc.
C12N9/1252C12N7/00C12Y207/07007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,371,028
App. No.
17/156,704
Granted
Jun 28, 2022
Kind
B2
Abstract

Variants of the bacteriophage B103 DNA polymerase are described herein. The variant has improved properties, that include when compared to wild-type Phi29 DNA polymerase, at least one of the following: increased thermostability, improved reaction rate for DNA amplification, reduced background and a reduction of bias. Methods of using the DNA polymerase variant are also described herein.

Claims (17)

1. A method, comprising:

combining with a target DNA, a DNA polymerase with an amino acid sequence that has at least 99% sequence identity with SEQ ID NO:5; and

amplifying the target DNA.

2. The method according to claim 1 , further comprising amplifying the target DNA in a high salt buffer.

3. The method according to claim 1 , further comprising amplifying the target DNA at a temperature in the range of 30° C.-42° C.

4. The method according to claim 3 , further comprising obtaining reduced sequence bias of the substrate DNA with the polymerase in claim 1 compared to the wild-type Phi29 DNA polymerase under the same reaction conditions.

5. The method according claim 3 , further comprising obtaining a higher rate of amplification compared to the rate of amplification using wild-type Phi29 DNA polymerase under the same reaction conditions.

6. The method according to claim 3 , further comprising obtaining an improved amplification yield after a reaction time of 2 hours compared to the yield obtained with wild-type Phi29 DNA polymerase under the same reaction conditions.

7. The method according to claim 1 , further comprising amplifying the target DNA in a high salt buffer.

8. A method, comprising:

combining with a target DNA, a DNA polymerase with an amino acid sequence that has at least 95% sequence identity with SEQ ID NO:2 and has at least one, two, three, four, five, six or seven amino acid substitutions at positions selected from the group consisting of: 147, 221, 318, 503, 511, 544 and 550; and

amplifying the target DNA.

9. The method of claim 8 , wherein the one to seven substitutions are selected from the group of substitutions consisting of: A147K, R221Y, A318G, A503M, I511V, R544K and T550K.

10. The method according to claim 8 , further comprising amplifying the target DNA at a temperature in the range of 30° C.-42° C.

11. The method according to claim 8 , further comprising obtaining an improved representation of the substrate DNA compared to the biased representation of wild-type Phi29 DNA polymerase under the same reaction conditions.

12. The method according claim 8 , further comprising obtaining a higher rate of amplification compared to the rate of amplification using wild-type Phi29 DNA polymerase under the same reaction conditions.

13. The method according to claim 8 , further comprising obtaining an improved yield of amplification after a reaction time of 2 hours compared to the yield obtained with wild-type Phi29 DNA polymerase under the same reaction conditions.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2021
From: ONG, JENNIFER; TANNER, NATHAN; ZHANG, YINHUA; BEI, YANXIA; POTAPOV, VLADIMIR
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 055280/0820 →
Cited By (2)
US 12,227,774 US 12,577,544